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In spite of the fact that commercial bromelain supplements are available in the market, to date, none of 
them are produced and formulated from recombinant forms. They are extracted and purified (often 
partially) from the stem and fruit of pineapple (Ananas comosus). This makes the production of 
bromelain very difficult, less reliable, often contaminated and expensive. In this study, a recombinant 
bromelain was expressed as soluble (active) and insoluble (inactive) enzyme in Escherichia coli BL21-
A1. The enzyme fractions were purified using Ni-NTA His•Bind resin with the aid of an automated fast 
protein liquid chromatography (FPLC) system. Purification fold and percentage yield of the purified 
active bromelain were found to be 3.7 and 64%, respectively. SDS-PAGE results showed that the 
enzyme was purified to near homogeneity and the soluble form exhibited a single band with molecular 
weight of about 45 kDa. 
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INTRODUCTION 
 
Plant tissues, animal organs and microorganisms are the 
most important sources of proteins and enzymes. For 
instance, enzymes from plants and animals, mostly pro-
teases, are still in the markets and some of them are of 
commercial relevance. Proteases are enzymes that 
catalyse the hydrolysis of peptide linkages in proteins. 
Industrially, proteases are the most important type of 
enzymes as they constitute about 60% of all commercial 
enzymes in the world (Lucia and Tomas, 2010). They are 
largely used in food, pharmaceutical and detergent 
industries.  
Microbial enzymes have been substituting those 
obtained from other sources and might now account for 
almost 90% of the total market (Illanes, 2008). This is due 
to the fact that microbial cells are excellent systems for 
enzyme production. In fact, they are metabolically 
vigorous, very versatile, easy to propagate, simple to 
manipulate, possess simple nutritional requirements and 
their supply is independent of season. These factors 
have stimulated extensive research works on  recombinant 
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proteins. 
The use of purified proteins for therapeutic purposes 
has been in existence for many decades. Hormones such 
as insulin and human growth hormones, and other 
proteins were extracted and purified from blood and other 
tissues before the emergence of recombinant DNA 
technology (Paul, 2004). Enzymes constitute the largest 
portion of these purified proteins for industrial and 
therapeutic applications. Since the approval of insulin in 
1982, hundreds of recombinant drugs including enzymes 
have been approved and become available as extremely 
valuable therapeutic options (Theo, 2008).  
The name ‘bromelain’ was originally given to a mixture 
of proteases found in the juice of the stem and fruit of 
pineapple (Ananas comosus). Even now, bromelain is 
still used as collective name for the enzymes found in 
various members of Bromeliaceae family. The major 
peptidase present in the extracts of plant stem is called 
‘stem bromelain’ while the major enzyme fraction found in 
the juice of pineapple fruit is called ‘fruit bromelain’. Some 
other minor cysteine endopeptidases (ananain, como-
sain) are also present in the pineapple stem bromelain.  
Stem bromelain (E.C. 3.4.22.32), belonging to papain 
family, is a glycosylated single chain protein containing of 
212 amino acid residues including  seven  cysteines,  one  
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of which is involved  in  catalysis  (Bitange  et  al.,  2008). 
Pure stem bromelain is stable when stored at −20°C and 
has optimum pH activity at 6 to 8.5. The optimum 
temperature range for the enzyme is 50 to 60°C. It is 
mostly activated by cysteine while hydrogen sulphide and 
sodium cyanide are less effective (Maurer, 2001). 
However, heavy metals (like mercury and silver) and 
E−64 deactivate the enzyme. 
Bromelain also has great therapeutic applications. It 
was firstly introduced as a therapeutic compound in 1957 
(Gregory and Kelly, 1996). Bromelain actions include: (i) 
inhibition of platelet aggregation; (ii) fibrinolytic activity; 
(iii) anti-inflammatory action; (iv) anti-tumour action; (v) 
modulation of cytokines and immunity; (vi) skin debride-
ment properties; (vii) enhanced absorption of other drugs; 
(viii) mucolytic properties; (ix) digestive assistance; (x) 
enhanced wound healing; and (xi) cardiovascular circula-
tory improvement (Gregory and Kelly, 1996). It is also 
used in food processing and baking industry (Lyons, 
1982), meat tenderization and as a dietary supplement 
(Ravindra et al., 2008). 
The use of conventional methods renders the produc-
tion and formulation of bromelain very challenging, less 
reliable, often contaminated and expensive. Moreover, 
downstream processing is one of the major cost factors 
(up to 50%) in bioprocess. Hence, it is vital to develop 
efficient and cost effective processes that contribute 
towards the development of highly purified and cheaper 
bromelain. This study was geared towards the recovery 
of recombinant bromelain that were over expressed in E. 
coli BL21-A1. 
 
 
MATERIALS AND METHODS 
 
Luria Bertani (LB) growth media used was a product of Merck, 
Germany. L−Cysteine, L−arabinose and N--Cbz-L-Gln-p-
nitrophenyl ester were purchased from Sigma Chemicals (USA). All 
other chemicals used were pure and of analytical grade.  
BL21-A1 Escherichia coli strain was obtained from Invitrogen 
(USA) and used throughout the study.  
 
 
Over expression of recombinant bromelain 
 
E. coli cells harboring recombinant bromelain gene were grown 
over night in Luria Bertani (LB) media, containing 100 µg/ml 
ampicillin (Amid et al., 2011). The overnight culture was then diluted 
100 fold in a fresh LB media containing 100 µg/ml ampicillin and 
was grown at 37°C and agitated at 250 rpm in shake flasks and 
then a 2-L bioreactor up to a cell density with OD600nm = 0.4. Inducer 
(L-arabinose) was then added to reach a final concentration of 
0.2% and the induction continued for 4 h. Cells were harvested 
from the spent media by centrifugation (8,000 rpm, 4°C and 20 min) 
and stored at −20°C until required for use (Ismail and Amid, 2008a 
and b). 
 
 
Recovery of recombinant bromelain 
 
The harvested cells were subjected to sonication (sonicator, 150v/t 
model, Biologics, Inc. USA) on ice using 6 to 10 s burst with 10 s 
interval at high amplitude.  This  was  followed  by  centrifugation  at  
 
 
 
 
12000 rpm and 4°C for 30 min and the supernatant was collected 
and purified by AKTA purifier FPLC system (GE Healthcare Bio-
Sciences, USA). The enzymes were purified under native and 
denaturing conditions according to the manufacturer’s instructions. 
A glass column for chromatography (4.6 × 100 mm, Life Technolo-
gies, California) was filled with 1 ml of Ni-NTA His•Bind resin 
(Novagen, Germany). The FPLC system was set at flow rate of 1 
ml/min.  
 
 
Protein determination 
 
The concentration of proteins present in the enzyme preparations 
were determined by Bradford’s (1976) method using bovine serum 
albumin as standard. 
 
 
SDS-PAGE  
 
After each step of enzyme recovery and purification, the protein 
fractions were tested by SDS-PAGE in 12.5% polyacrylamide gels 
and visualization was performed by staining with Coomasie Brilliant 
blue R-250 (Laemmli, 1970). 
 
 
Measurement of proteolytic activity 
 
The assay for proteolytic activity was carried out by the Silverstein’s 
(1974) method and modified to reach optimal conditions of the 
enzyme. The activity was studied using N--Cbz-L-Gln-p-
nitrophenyl ester as substrate. Assays were made at 37°C in 0.1 M 
Tris–HCl buffer (pH 8.0), containing 25 mM cysteine and 1 mM of 
the substrate in the reaction mixture. Liberation of p-nitrophenol 
was followed spectrophotometrically at 405 nm (Secomam-Anthelie 
5, France). An arbitrary enzyme activity unit (Ucbz) was defined as 
the amount of protease that released one micromole of p-
nitrophenolate per min in the assay conditions (Maria et al., 2008). 
 
 
RESULTS AND DISCUSSION 
 
Recombinant bromelain was successfully expressed in E. 
coli BL21-AI as native (soluble) and denatured (insoluble) 
enzyme as presented in Figure 1. The samples from 
each step of the purification technique were analyzed by 
SDS-PAGE as shown in Figure 1a and c for soluble and 
insoluble bromelain, respectively. It could be seen clearly 
from these figure that only few target proteins were eluted 
in unbinding fractions and the bromelain was purified to 
almost homogeneity in one affinity purification step. The 
molecular weight of the purified soluble enzyme (contain-
ing six-His tag) was found to be approximately 45 kDa on 
SDS–PAGE (Figure 1b). This value closely correlated 
with the size of the natural bromelain gene (D14059.1). 
Moreover, the value fell within the range of molecular 
masses of plant cysteine proteases (25 to 75 kDa) as 
reported by Dubey et al. (2007). Soluble recombinant 
proteins often have correctly folded three-dimensional 
conformation; hence, normally bioactive in nature (Hans 
and Kim, 2005). However, the insoluble protein has 
unfolded structural conformation. This explains why 
single band was obtained for soluble bromelain (Figure 
1a and b), while multiple bands were seen in the inso-
luble form (Figure 1c). The various  bonds  stabilizing  the  
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Figure 1. SDS-PAGE analysis of the purification of recombinant bromelain expressed in E.coli BL21-AI. (a) 
SDS-PAGE showing different purification steps of soluble (native) bromelain. Lane M: Protein molecular weight 
marker; lane 1: Crude cell lysate; lane 2: Flow through of binding step; lane 3: Washing step; lanes 4 and 5: 
Eluted purified soluble recombinant bromelain. (b) SDS-PAGE showing purified soluble bromelain. Lane M: 
Protein molecular weight marker; lanes 1, 2, 3 and 4: Purified soluble recombinant bromelain. (C) SDS-PAGE 
showing different purification steps of insoluble (denatured) bromelain. Lane M: Protein molecular weight 
marker; lanes 1 and 2: Crude cell lysate; lane 3: Washing step; lanes 4 and 5: Eluted purified insoluble 
recombinant bromelain. 
 
 
 
tertiary structure of the protein was disrupted in the 
insoluble form. The unfolded proteins (Figure 1c) might 
have trapped and/or interacted with some proteins during 
purification process. 
The purification results for  recombinant  bromelain  are  
summarized and shown in Table 1. It can be observed 
that the purification fold for both native (soluble) and 
denatured (insoluble) bromelains were 3.7 and 2.7, while 
their corresponding yield (%) was 64 and 60.5, respec-
tively. This implies that higher purification factor (PF)  and
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Table 1. Purification of recombinant bromelain of E. coli BL21-AI. 
 
Protein fraction Volume (ml) 
Total activity 
(U) 
Total protein 
(mg) 
Specific activity 
(U/mg) 
Purification 
fold 
Yield 
(%) 
Crude (Soluble) 10 2572 41.2 62.4 1.0 100 
Purified (soluble) 2.7 1646 7.2 228.6 3.7 64.0 
Crude (insoluble) 10 476 26.8 17.8 1.0 100 
Purified (insoluble) 2.5 288 5.9 48.8 2.7 60.5 
 
 
 
yields were obtained in the soluble form of bromelain. 
The recovery of soluble protein from inclusion bodies 
often yield less active enzyme and can significantly raise 
the cost of bioseparation (Lilie et al., 1998). Consequent-
ly, it is vital to express the protein in a soluble and 
biologically active form. The values of PF and yield of 
soluble bromelain obtained from this study were found to 
be slightly higher as compared to 2.11 and 47.5% 
obtained by Xu et al. (2011) for recombinant glycerol 
dehydratase. In addition to this, Krishna et al. (2011) 
obtained 2.5 and 46% for recombinant protein 
(hGMCSF). Both proteins mentioned earlier were purified 
by using Ni-NTA affinity chromatography technique as 
well. It could be seen that higher PF and yield values for 
soluble bromelain were achieved. 
 
 
Conclusion 
 
It can be concluded that this study had achieved the 
successful expression of recombinant bromelain. The 
soluble and insoluble forms of the enzyme were purified 
to near homogeneity by one-step Ni-NTA His•Bind affinity 
chromatography. Higher yield and purification factor was 
attained in the production of soluble form of bromelain. 
Finally, soluble bromelain of molecular weight of about 45 
kDa has been produced. 
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